CEA Antibody - CEACAM5 Tumor Marker for Cancer Research

CEA (CEACAM5) Antibodies for Tumor Marker Research

Carcinoembryonic antigen (CEA), encoded by CEACAM5 and also known as CD66e, is a well-established epithelial tumor marker widely used in cancer research. CEA antibodies are commonly used to detect CEACAM5 expression in epithelial-derived tissues and tumors, where expression is frequently elevated and redistributed compared to normal physiological conditions. In normal tissues, CEA is typically localized to the apical surface of epithelial cells in gastrointestinal and glandular tissues, while malignant transformation is associated with increased expression and broader membranous and cytoplasmic distribution.

CEA antibody reagents support detection of epithelial tumor cells, evaluation of tumor-associated antigen expression, and studies of epithelial differentiation. Because CEACAM5 expression is largely restricted to epithelial lineages, CEA antibodies are widely used to distinguish carcinomas from non-epithelial malignancies and to investigate tumor origin in complex tissue samples.

Applications of CEA Antibodies

CEA antibodies are used across multiple research applications to study CEACAM5 expression and tumor biology. In immunohistochemistry, CEA antibodies enable visualization of epithelial architecture and tumor cell populations in formalin-fixed, paraffin-embedded tissues, with characteristic membranous and luminal staining patterns in normal tissues and expanded distribution in malignancy.

In addition to tissue-based analysis, CEA antibodies are used in immunodetection assays such as ELISA and western blot to quantify or confirm CEACAM5 expression in biological samples. These complementary approaches support both qualitative and quantitative analysis of carcinoembryonic antigen across different experimental systems.

CEA Expression Patterns in Normal and Cancer Tissues

CEA expression follows a well-defined pattern in normal epithelial tissues, where staining is typically restricted to luminal and apical surfaces. In contrast, tumor tissues often exhibit increased expression and loss of polarized distribution, resulting in more diffuse membranous and cytoplasmic staining in carcinoma cells. These changes reflect alterations in epithelial organization and cell adhesion associated with malignant transformation.

Across multiple carcinoma types, including colorectal, gastric, pancreatic, and lung adenocarcinomas, CEA expression is frequently elevated, making it a reliable marker for epithelial tumor detection and classification. The contrast between epithelial tumor cells and surrounding non-epithelial tissues enhances interpretability in tissue-based assays and supports its use in tumor profiling studies.

Tissue Microarray (TMA) Analysis of CEA Antibodies

Tissue microarray (TMA) analysis enables large-scale evaluation of CEA expression across diverse normal and cancer tissues under standardized experimental conditions. CEA antibodies applied to TMA panels allow direct comparison of staining patterns across hundreds of tissue cores, providing a comprehensive view of CEACAM5 distribution.

In TMA-based studies, strong tumor-associated staining is observed in epithelial malignancies alongside minimal background in non-epithelial tissues, reinforcing the specificity of CEA as a tumor marker. This high-throughput approach supports biomarker validation, comparative tissue analysis, and large-scale cancer research applications.

Explore CEA Antibody Products

A range of CEA antibody reagents are available to support different research applications, including immunohistochemistry and other immunodetection assays. These antibodies enable reliable detection of CEACAM5 expression across a variety of sample types and experimental formats.

A selection of CEA antibody products is shown below to support a range of research applications.